Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept vs FOLFOX in Elderly mCRC
NCT03530267Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Sep 2018
- Primary completion
- Feb 2024
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in metastatic colorectal cancer (mCRC), sponsored by Institut für Klinische Krebsforschung. Started Sep 2018; status: completed.
02
Drugs
aflibercept
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03530267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03530267.